Hormone replacement therapy public meeting
Executive Summary
National Institutes of Health will host a public meeting to discuss results of the Women's Health Initiative trial Oct. 23-24 at 8:30 a.m. in the Natcher Conference Center. The trial was halted in July after a finding of an increased risk of breast cancer and adverse cardiovascular outcomes among subjects on Wyeth's Prempro (progestin/medroxyprogesterone) (1"The Pink Sheet" July 15, p. 11). FDA plans to host a public session in the fall to discuss whether the WHI results can be extrapolated to other combination estrogen/progestin products (2"The Pink Sheet" Aug. 19, p.11). The U.S. Preventive Services Task Force, sponsored by the Agency for Healthcare Research & Quality, plans to make public new recommendations on hormone replacement therapy use in the fall, NIH said...
You may also be interested in...
Premarin/Prempro Rxs Stabilize; Wyeth Predicts $300 Mil. Drop In 2nd Half
Wyeth is seeing some stabilization in the Premarin franchise despite a 40% drop in prescriptions for Prempro and a 15% decline in Premarin scripts since release of the Women's Health Initiative study results
Wyeth Prempro Updated Label Submission Soon; HHS To Discuss WHI Results
Wyeth expects to submit updated Prempro labeling reflecting the results of the Women's Health Initiative study on use of the hormone replacement therapy soon, the company said
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Wyeth is sending letters to approximately 550,000 physicians as part of a Prempro risk management program to address risks associated with use of the hormone combination for cardiovascular disease and osteoporosis prevention